Zydus Cadila's ZyCoV-D vaccine, the plasmid DNA vaccine, is in an advanced stage of Phase III clinical trials and the data is expected to be submitted to the regulators in June. 

Continuing with its relentless efforts on battling COVID-19 with diagnostics, therapeutics and vaccines, the company has also launched Virafin (Pegylated Interferon alpha-2b (PegIFN) to treat moderate infection in adult COVID-19 patients during the quarter. 

Making headway in its innovation programme, the company completed the patient enrolment in DREAM-ND and DREAM-D Phase III trials of Desidustat in India, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD) during the year. 

In another development, Zydus Cadila has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year. 

Earnings before Interest, Depreciation and Tax (EBITDA) grew by 8% on a y-o-y basis to Rs. 855 crores during the fourth quarter. Net Profit was up by 73% on a y-o-y basis to Rs. 679 crores during the fourth quarter. 

For the year ended March 31st, 2021, on a consolidated basis, the company registered the total income from operations of Rs. 15,102 crores, up by 6%. The EBITDA for the year of Rs. 3,341 crores registered 20% growth over the previous year whereas net profit for the year was Rs. 2,134 crores. 

The company’s business in India geography which comprises human health formulations business, consumer wellness business and animal health business posted a strong growth during the quarter as it grew by 18% on a y-o-y basis and registered revenues of Rs. 1,772 crores. Human health formulations business in India grew by 15% and consumer wellness business grew by 22% on a y-o-y basis during the quarter. 

US formulations business registered revenues of Rs. 1,509 crores during the quarter. Strengthening its regulatory pipeline, the company filed 22 additional ANDAs during the year with the USFDA, taking the cumulative filings to 412. The company received 35 ANDAs approvals during the year, taking the total to 317 product approvals.